secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2026-09-10T20:05:43+00:00
Accession:  0001104659-26-106705
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
--------------------------------------------------------------------------------

- Second RPD designation for QRX003; first was for Netherton Syndrome.
- If NDA approved, Quoin may receive a Priority Review Voucher (PRV), which can be sold or transferred.
- Phase 2 study expected to initiate in 2H 2026, enrolling up to 12 pediatric and adult PSS patients in U.S. and Europe.
- No approved treatments currently exist for Peeling Skin Syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926106705/0001104659-26-106705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465926106705/tm2625203d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-106705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer